Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Judd Gregg: Biodefense Funding Is Crucial to National Security

ebola

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs in preparing our nation for viral outbreaks and other biohazards that threaten to cause devastating harm to our national security. Because there is no commercial market for medical countermeasures to respond to attacks from chemical, biological, nuclear and radiological threats, in 2004 Congress passed the Project BioShield Act, which created the Project BioShield Special Reserve Fund (SRF) to incentivize research Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

JAMA Study Finds Vast Majority of Requests for Clinical Trial Data Granted

cells115x76

In 2014, BIO members reaffirmed and broadened their commitment to responsibly share data from clinical trials with other researchers, including academic and government researchers, in an effort to support additional efforts to improve public health. A JAMA study released yesterday shows that biopharmaceutical companies are keeping that commitment, approving the vast majority of requests for patient-level data from clinical trials. The study looked at three platforms containing clinical trial data from 14 drug companies. Of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

ICYMI: John Lechleiter: An Empty Obama-Clinton-Sanders Plan on Drug Costs

Wall Street Journal

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO John Lechleiter examines proposals that would require pharmaceutical companies to disclose detailed information about the cost of R&D for individual drugs and the extent of discounts offered to insurers for each drug. Such proposals have been advanced in President Obama’s budget and on the campaign trail by Bernie Sanders and Hillary Clinton. But as Lechleiter explains, the key numbers are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Guardian: Global defence system to fight virus threats urgently needed

ebola

Fresh on the heels of the recent Ebola epidemic, the current Zika virus threat has many asking what to better prepare for such infectious disease outbreaks. Writing in The Guardian, Trevor Mundel of the Gates Foundation and Jeremy Farrar of the Wellcome Trust have some suggestions: A healthy body has three essential systems for staying that way. There is physical fitness, building resilience against threats. There is the brain, to spot danger and take action. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Reality Check for AARP

lab_tech

This morning, AARP released yet another misleading report on prescription drug prices that ignores key facts about the marketplace for medicines. The report suffers from several notable flaws. Most glaringly, AARP underplays the value of the Medicare Part D program and ignores the stability in the program brought about by market competition: Average annual out of pocket spending on drugs for Medicare Part D beneficiaries has fallen in recent years, declining 16 percent between 2007 Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,